Yunnan Baiyao to Invest 360 Million Yuan in Wuxi Transdermal Drug Delivery Technology Platform

Stock News06-24

Yunnan Baiyao Group Co.,Ltd. (SHE: 000538) has announced that its board of directors has approved a proposal to construct a transdermal drug delivery technology industrial platform project in Wuxi.

The project, with a total investment budget of 360 million yuan, will be undertaken by the company's wholly-owned subsidiary, Yunnan Baiyao Group Wuxi Pharmaceutical Co., Ltd.

The platform is designed to cover three major product pipelines: ensuring supply for core mature products, facilitating the launch of innovative and upgraded products, and developing a pipeline for new dosage forms.

This initiative aims to comprehensively address the full spectrum of needs, including deepening the development of core orthopedic trauma categories, expanding into high-end transdermal preparations, and incubating innovative dosage forms.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198414403?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 18:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198414403","market":"hk","top_or_hot":-1,"title":"Yunnan Baiyao to Invest 360 Million Yuan in Wuxi Transdermal Drug Delivery Technology Platform","media":"Stock News","content":"<p><b>Yunnan Baiyao Group Co.,Ltd.</b> (<b>SHE: 000538</b>) has announced that its board of directors has approved a proposal to construct a transdermal drug delivery technology industrial platform project in Wuxi.<br><br>The project, with a total investment budget of 360 million yuan, will be undertaken by the company's wholly-owned subsidiary, Yunnan Baiyao Group Wuxi Pharmaceutical Co., Ltd.<br><br>The platform is designed to cover three major product pipelines: ensuring supply for core mature products, facilitating the launch of innovative and upgraded products, and developing a pipeline for new dosage forms.<br><br>This initiative aims to comprehensively address the full spectrum of needs, including deepening the development of core orthopedic trauma categories, expanding into high-end transdermal preparations, and incubating innovative dosage forms.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yunnan Baiyao to Invest 360 Million Yuan in Wuxi Transdermal Drug Delivery Technology Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYunnan Baiyao to Invest 360 Million Yuan in Wuxi Transdermal Drug Delivery Technology Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-24 18:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Yunnan Baiyao Group Co.,Ltd.</b> (<b>SHE: 000538</b>) has announced that its board of directors has approved a proposal to construct a transdermal drug delivery technology industrial platform project in Wuxi.<br><br>The project, with a total investment budget of 360 million yuan, will be undertaken by the company's wholly-owned subsidiary, Yunnan Baiyao Group Wuxi Pharmaceutical Co., Ltd.<br><br>The platform is designed to cover three major product pipelines: ensuring supply for core mature products, facilitating the launch of innovative and upgraded products, and developing a pipeline for new dosage forms.<br><br>This initiative aims to comprehensively address the full spectrum of needs, including deepening the development of core orthopedic trauma categories, expanding into high-end transdermal preparations, and incubating innovative dosage forms.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"","article_id":"1198414403","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198414403","pubTimestamp":1782295858,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Yunnan Baiyao Group Co.,Ltd. (SHE: 000538) has announced that its board of directors has approved a proposal to construct a transdermal drug delivery technology industrial platform project in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0175":"白马股","000538":"云南白药","BK0196":"行业龙头","BK0187":"一线龙头","BK0028":"国家队","BK0239":"医药制造","BK0164":"国企混改","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","BK0188":"融资融券","BK0012":"证金概念"},"translate_title":"云南白药将3.6亿元投建无锡透皮给药技术平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000538":1},"content_text":"Yunnan Baiyao Group Co.,Ltd. (SHE: 000538) has announced that its board of directors has approved a proposal to construct a transdermal drug delivery technology industrial platform project in Wuxi.The project, with a total investment budget of 360 million yuan, will be undertaken by the company's wholly-owned subsidiary, Yunnan Baiyao Group Wuxi Pharmaceutical Co., Ltd.The platform is designed to cover three major product pipelines: ensuring supply for core mature products, facilitating the launch of innovative and upgraded products, and developing a pipeline for new dosage forms.This initiative aims to comprehensively address the full spectrum of needs, including deepening the development of core orthopedic trauma categories, expanding into high-end transdermal preparations, and incubating innovative dosage forms.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198414403","isCrawlerRequest":true}